TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15738298
Drug: Topical decongestant
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical decongestant and external dilator strip
Study: 15738298
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and sham treatment
Study: 15321623
Drug: Thromboembolic deterrent
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thromboembolic deterrent stockings (TED) and sequential compression device (SCD)
Study: 2499203
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg praziquantel
Study: 16084181
Drug: Access to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access to drug samples
Study: 16084181
Drug: No access
Approvals — FDA: no, EMA: no, PMDA: no
Description: No access to drug samples
Study: 3176837
Drug: Buprenorphine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.6 mg in 20 ml NaCl)
Study: 3176837
Drug: Naloxone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.4 mg in 20 ml NaCl)
Study: 31743542
Drug: 1% BOI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% BOI lotion (ceramide HS) applied once a day for 6 months
Study: 19579946
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation (15 drops)
Study: 19579946
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron supplementation (30 drops)
Study: 19579946
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of daily vs weekly iron supplementation
Study: 14982566
Drug: Dextromethorphan (270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (270 mg)
Study: 11338024
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery (pleuropneumonectomy) followed by sequential chemotherapy and radiotherapy
Study: 11338024
Drug: Single-modality therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-modality therapy (surgery, radiotherapy, chemotherapy)
Study: 8170529
Drug: quazepam (15-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: quazepam (15-30 mg, median 15 mg)
Study: 8170529
Drug: triazolam (0.25-0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: triazolam (0.25-0.5 mg, median 0.25 mg)
Study: 18776000
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy alone (COMPANION)
Study: 18776000
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy plus implantable cardioverter defibrillator (COMPANION)
Study: 18776000
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy alone (CARE-HF)
Study: 17161052
Drug: Noninvasive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive treatment strategy
Study: 10805207
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) via pressurized metered-dose inhaler (MDI)
Study: 27009822
Drug: Oral NTHi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral NTHi vaccine (HI-164OV)
Study: 24769011
Drug: Insulin-dependent diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-dependent diabetes group
Study: 15741989
Drug: L-carnitine 1
Normalized name: L-Carnitine 1,000mg Oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine 1 g orally three times a day for 12 weeks
Study: 9800081
Drug: Vestibular rehabilitation
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular rehabilitation therapy
Study: 361463
Drug: Mazindol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazindol (2 mg/day for 12 weeks)
Study: 28619061
Drug: Rituximab 1
Normalized name: rituximab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 1 g intravenously, twice at an interval of 2 weeks
Study: 28619061
Drug: Cyclophosphamide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 600 mg/m2 body surface area intravenously, given monthly
Study: 26341455
Drug: Early feeding
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early feeding (fasting for 4 hours after endoscopic therapy)
Study: 26341455
Drug: Delayed feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed feeding (fasting for 48 hours after endoscopic therapy)
Study: 20427425
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of a megadose of cholecalciferol (10,000 IU kg(‐1), max 600,000 IU)
Study: 20427425
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of a megadose of cholecalciferol
Study: 18777031
Drug: AS100 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS100 vaccine
Study: 16919747
Drug: Levomethadyl acetate
Normalized name: Levomethadyl acetate
DrugBank: Levacetylmethadol (DB01227)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levomethadyl acetate (LAAM), 255-391 mg
Study: 16919747
Drug: Buprenorphine (BUP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (BUP), 56-112 mg
Study: 16919747
Drug: Methadone (METH),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (METH), 420-700 mg
Study: 9105981
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received 5 mg of epidural morphine after intubation
Study: 8478661
Drug: IL-2/IFN (IL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2/IFN (IL-2 0.8 mg/m2 and IFN 3 x 10(6) U/m2)
Study: 8478661
Drug: IL-2 alone
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 alone (1.33 mg/m2)
Study: 2429335
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg piroxicam each morning
Study: 2429335
Drug: Therapeutic exercise
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic exercise (conservative treatment)
Study: 25692797
Drug: Financial incentives
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Financial incentives for medication adherence
Study: 22978687
Drug: TSH >30
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSH >30 μU/mL after 4 weeks of thyroid hormone withdrawal (THW)
Study: 22978687
Drug: TSH >80-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSH >80-100 μU/mL after 4 weeks of THW
Study: 22978687
Drug: TSH >20
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSH >20 μU/mL with Tg <0.2 ng/mL
Study: 16816226
Drug: Family focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family focused grief therapy (53 families, 233 individuals)
Study: 9219391
Drug: Fluoxetine as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine as an adjunct to treatment for cocaine abuse
Study: 3591689
Drug: Dobutamine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine therapy at incremental doses of 2.5, 5, 7.5, 10, 12.5 and 15 micrograms/kg/min
Study: 3591689
Drug: Milrinone as
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone as a bolus of 50 or 75 micrograms/kg followed by an infusion of 0.5 to 1.0 micrograms/kg/min
Study: 25767373
Drug: Revexepride 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revexepride 1 mg
Study: 25767373
Drug: Revexepride 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revexepride 1 mg + Omeprazole 40 mg
Study: 9282236
Drug: Turbuhaler (TH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbuhaler (TH) with 0.5 mg terbutaline
Study: 9282236
Drug: pressurized metered-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: pressurized metered-dose inhaler (pMDI) with 0.5 mg terbutaline
Study: 9282236
Drug: pressurized metered-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: pressurized metered-dose inhaler (pMDI)
Study: 8334346
Drug: Sheng Mai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sheng Mai injection
Study: 3113147
Drug: Naloxone administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone administration (8 mg iv as a bolus followed by an infusion of 4 mg/h for 4 h)
Study: 3113147
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (200 mg im every two weeks)
Study: 22032285
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy (2 L/min through nasal prongs)
Study: 22032285
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy and ASV
Study: 21170109
Drug: S-Gel 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-Gel 5.0 g
Study: 21170109
Drug: S-Gel 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-Gel 7.5 g
Study: 17971716
Drug: CD4 cell
Normalized name: lisocabtagene maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD4 cell count-guided episodic antiretroviral therapy
Study: 21596364
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg) added to stable rosuvastatin 5 mg or 10 mg
Study: 21596364
Drug: Ezetimibe plus
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe plus rosuvastatin 5 mg
Study: 21596364
Drug: Ezetimibe plus
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe plus rosuvastatin 10 mg
Study: 21596364
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg) added to stable rosuvastatin
Study: 21596364
Drug: Rosuvastatin up-titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin up-titration
Study: 16275885
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sildenafil twice daily for 4 weeks
Study: 11865971
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg Cenestin (Synthetic Conjugated Estrogens, A) tablets, administered once daily for 90 days
Study: 2505269
Drug: BCG (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG (150 mg)
Study: 2505269
Drug: ADM (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADM (50 mg)
Study: 2505269
Drug: TTPA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTPA (50 mg)
Study: 11514481
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment for secondary prevention of coronary heart disease (CHD)
Study: 11514481
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment for primary prevention at CHD risk 30% over 10 years
Study: 11514481
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment for primary prevention at CHD risk 20% over 10 years
Study: 11514481
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment for primary prevention at CHD risk 15% over 10 years
Study: 11514481
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment for primary prevention at CHD risk 6% over 10 years
Study: 11514481
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment at projected CHD risk 20% over 10 years
Study: 30873671
Drug: Black seed
Normalized name: BLACK SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black seed capsules (500 mg) two times per day for 10 weeks
Study: 27378000
Drug: Preoperative dexketoprofen
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative dexketoprofen trometamol (25 mg 30 min before surgery)
Study: 27378000
Drug: Postoperative dexketoprofen
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative dexketoprofen trometamol (25 mg immediately after surgery)
Study: 20199786
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Simvastatin + Ezetimibe)
Study: 15889952
Drug: Oral quetiapine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral quetiapine (493 mg/day at week 48)
Study: 15889952
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol decanoate (170 mg/28 days at week 48)
Study: 8671571
Drug: High titre
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High titre measles vaccine
Study: 8671571
Drug: Medium titre
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium titre measles vaccine
Study: 8671571
Drug: High titre
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High titre measles vaccine (females)
Study: 8671571
Drug: High titre
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High titre measles vaccine (males)
Study: 8671571
Drug: Standard titre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard titre measles vaccine
Study: 1931060
Drug: Thiopental sodium
Normalized name: Thiopental Sodium
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopental sodium (1.0 mg/kg to 4 mg/kg)
Study: 6210665
Drug: mezlocillin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: mezlocillin (1.5 g) administered intramuscularly every 6 hr for seven to ten days
Study: 6210665
Drug: ticarcillin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ticarcillin (2 g) administered intramuscularly every 6 hr for seven to ten days
Study: 30672213
Drug: Climen tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Climen tablet prescribed orally from the 5th day of menstruation, one tablet a time, once a day for 3 months (7 days between two 21-day medication).
Study: 20667889
Drug: posaconazole 400
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: posaconazole 400 mg twice daily
Study: 20667889
Drug: fosamprenavir/ritonavir 700/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: fosamprenavir/ritonavir 700/100 mg twice daily
Study: 20667889
Drug: posaconazole 400
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: posaconazole 400 mg twice daily with fosamprenavir 700 mg twice daily
Study: 11973215
Drug: Bupivacaine 0.0625%
Normalized name: BUPIVACAINE 0.0625%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.0625% plus fentanyl 2 microg/mL
Study: 11973215
Drug: Bupivacaine 0.125%
Normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.125% plus fentanyl 2 microg/mL
Study: 9454395
Drug: One injection
Normalized name: naloxone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection of penicillin
Study: 9454395
Drug: Penicillin tablets
Normalized name: Penicillin V
DrugBank: Meticillin (DB01603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin tablets for six days
Study: 8585875
Drug: Pravastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin therapy at a dose of 20 mg/die
Study: 8585875
Drug: Dietetic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietetic treatment and placebo after pravastatin suspension
Study: 23313720
Drug: Attention and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention and dose‐matched control program (n = 52)
Study: 10668412
Drug: CP-101,606 (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-101,606 (0.75 mg/kg/hr for 2 hours, then 0.37 mg/kg/hr for 22 or 70 hours)
Study: 2110537
Drug: Morniflumate suppositories
Normalized name: morniflumate
DrugBank: Morniflumate (DB09285)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morniflumate suppositories (400 mg, twice daily for 4 days)
Study: 2110537
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for 4 days)
Study: 31115111
Drug: Episodic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Episodic treatment for bleeding
Study: 19996674
Drug: Test group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test group implants placed 2 mm supracrestally
Study: 19996674
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group implants positioned at bone level
Study: 15145175
Drug: Proton-photon radiotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-photon radiotherapy, mean prescribed dose 76.3 CGE
Study: 11773293
Drug: Tamoxifen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen therapy for 1-3 years
Study: 11773293
Drug: Tamoxifen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen therapy for 5 years
Study: 11773293
Drug: Tamoxifen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen therapy for longer than 5 years
Study: 2888017
Drug: Glucocorticoid (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid (30 mg/kg bolus followed by 5 mg/kg/hour infusion for 9 hours)
Study: 2196240
Drug: TBF +
Normalized name: Trifluridine plus tipiracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBF + R administered in 3 office visits over 8 weeks
Study: 2196240
Drug: TBF +
Normalized name: Trifluridine plus tipiracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBF + R plus instruction in cognitive stress coping techniques administered in 5 office visits over 8 weeks
Study: 26206666
Drug: Nebulized racemic
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized racemic salbutamol solution
Study: 26206666
Drug: 3% sodium
Normalized name: Dextrose 5% and 0.3% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% sodium chloride (NaCl) solution
Study: 21788033
Drug: Leuprolide to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide to Degarelix (240/80 mg or 240/160 mg)
Study: 15452182
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (doxorubicin-based)
Study: 12410926
Drug: Butylscopolamine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butylscopolamine (intravenous injection)
Study: 9661636
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose load before surgery
Study: 9661636
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral glucose load before surgery
Study: 9661636
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion during post-op clamp
Study: 2651174
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release indomethacin 75 mg/day
Study: 333568
Drug: Sydnocarb (5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sydnocarb (5-15 mg)
Study: 23357210
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Doxazosin + Finasteride)
Study: 22289552
Drug: Continuous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous low-dose antibiotic (n = 37)
Study: 22289552
Drug: Single-dose antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose antibiotic (n = 31)
Study: 9673754
Drug: BIP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIP chemotherapy followed by radiotherapy (RT) in CT-RT Group
Study: 9673754
Drug: BIP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIP chemotherapy followed by RT in CT-RT Group (study 2)
Study: 8082875
Drug: Alprazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.5 mg orally)
Study: 2567266
Drug: Olsalazine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olsalazine (2 g/day)
Study: 2567266
Drug: Sulphasalazine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine (3 g/day)
Study: 31023432
Drug: Dietary fish-oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fish-oil supplementation of 2.5 g/day
Study: 17785037
Drug: E2V (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2V (1 mg) + MPA (2.5 mg)
Study: 17785037
Drug: E2V (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2V (2 mg) + MPA (5 mg)
Study: 17785037
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (E2V and MPA combinations)
Study: 15097809
Drug: Iodinated oral
Normalized name: iodine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodinated oral contrast (IOC)
Study: 7988628
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg twice daily for 3 days)
Study: 31930518
Drug: Cognitive Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Stimulation Therapy (CST) based on Roy's adaptation model
Study: 23991658
Drug: Edoxaban (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (60 mg once daily or 30 mg once daily for specific patients)
Study: 23991658
Drug: Warfarin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (in patients with pulmonary embolism and right ventricular dysfunction)
Study: 21911723
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 20 mg daily
Study: 21911723
Drug: Tamoxifen plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen plus octreotide (TAM-OCT) 90 mg depot monthly for 2 years
Study: 17900778
Drug: Treatment-resistant schizophrenia
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-resistant schizophrenia patients
Study: 17900778
Drug: Treatment-responsive chronic
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-responsive chronic schizophrenia patients